Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: A systematic review of randomized trials

American Journal of Cardiovascular Drugs

Volumn 7, Issue 2, 2007, Pages 135-141

  Bavry, Anthony A ^a   Mood, Girish R ^a   Kumbhani, Dharam J ^b   Borek, Peter P ^a   Askari, Arman T ^a   Bhatt, Deepak L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; COLESTYRAMINE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; TIROFIBAN; VERAPAMIL;

ACUTE CORONARY SYNDROME; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG WITHDRAWAL; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; MYOSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; ANTICHOLESTEREMIC AGENTS; CEREBROVASCULAR ACCIDENT; FEMALE; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34249009884     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200707020-00005     Document Type: Review

References (25)

1. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357: 1063-8
2. Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002; 287: 3087-95
3. Michels KB, Braunwald E. Estimating treatment effects from observational data: dissonant and resonant notes from the SYMPHONY trials. JAMA 2002; 287: 3130-2
4. Bavry AA, Bhatt DL. Interpreting observational studies: look before you leap. J Clin Epidemiol 2006; 59: 763-4
5. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study. A randomized controlled trial. JAMA 2001; 285: 1711-8
6. Briel M, Schwartz GG, Thompson PL, et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006; 295: 2046-56
7. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180-9
8. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
9. Arntz HR, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the random-ized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 2000; 86: 1293-8
10. Kayikcioglu M, Can L, Kultursay H, et al. Early use of pravastatin in patients with acute myocardial infarction undergoing coronary angioplasty. Acta Cardiol 2002; 57: 295-302
11. Liem AH, van Boven AJ, Veeger NJ, et al. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 2002; 23: 1931-7
12. Colivicchi F, Guido V, Tubaro M, et al. Effects of atorvastatin 80mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction. Am J Cardiol 2002; 90: 872-4
13. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504
14. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndromes: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event. The ESTABLISH study. Circulation 2004; 110: 1061-8
15. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-16
16. Califf RM, DeMets DL. Principles from clinical trials relevant to clinical practice: part I. Circulation 2002; 106: 1015-21
17. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9
18. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996; 335: 1001-9
19. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-22
20. Fonarow GC, Gheorghiade M, Abraham WT. Importance of in-hospital initiation of evidence-based medical therapies for heart failure-a review. Am J Cardiol 2004; 94: 1155-60
21. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78
22. Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering: are they clinically relevant? Eur Heart J 2003; 24: 225-48
23. Shishebor MH, Patel T, Bhatt DL. Using statins to treat inflammation in acute coronary syndromes: are we there yet? Cleve Clin J Med 2006; 73: 760-6
24. LUNAR IIIb: study comparing rosuvastatin and atorvastatin in subjects with acute coronary syndromes [online]. Available from URL: http://www. clinicaltrials.gov/ct/show/NCT00214360 [Accessed 2007 Mar 14]
25. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48: 438-45